We are very delighted to initiate this collaboration with InSilicoTrials and have the opportunity to optimize and accelerate our next clinical steps. Integrating their industry-leading AI and computational modeling solutions in the development plan of our promising disease-modifying drug will allow us to address the pressing challenges faced by individuals suffering from neurological disorders.

Since the birth of our company we have dreamed of carrying out a preclinical development of a vaccine or a monoclonal antibody while minimizing waste, which is why the LAB 4.0 project was born. We are now excited to partner with InSilicoTrials to take this concept further and extend it to the point where we can simulate the entire biopharmaceutical development chain from lab, to animal testing, to clinic, while dramatically reducing related risks.

The in silico option can transform trials for which it is difcult to recruit or retain patients, such as with rare or imminently life-threatening diseases, with no or inadequate standard of care Treatments. For clinical trials in small patient populations, in silico models that leverage biological, molecular, or genetic data to characterize the disease can generate synthetic control arms, which, together with Premier Research's expertise in preclinical and clinical development, execution, and regulatory aspects of small population trials, can shrink the time it takes to develop effective rare disease therapies.

Modeling and Simulation (M&S) has become firmly established as a regulatory science priority at FDA during the last decade, coinciding with the enormous expansion of data science and model-based technologies.

We are thrilled to this opportunity between DSTC and InSilicoTrials. In Japan, the in silico services are still at the dawning stage, but we are confident that by partnering with InSilicoTrials, a company with an excellent track record and experiences in the EU and the U.S., our clients will be able to share their global knowledge and experience success in the future of digitalization. Putting together InSilicoTrials’ expertise in modeling and simulation and ours in ion channel assay capabilities shall bring tremendous benefits to our shared customers.

We’re honored to have found the perfect partner in InSilicoTrials. RCPE and InSilicoTrials are combining their expertise to help engineers and researchers make data-driven decisions and deliver new levels of innovation. InSilicoTrials‘ comprehensive simulation platform combined with XPS creates a single-source repository for pharmaceutical development from discovery to dosage form. This collaboration and our shared developmental efforts truly set the gold standard for modeling and simulation in life sciences.

We believe that the partnership with InSilicoTrials will further strengthen our analytical know-how and expertise, improving efficiency in our production processes, and reinforcing our continuous effort to innovate responsibly.